Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
anti basal ganglia antibodies
anti-dopamine 2 receptor antibody
apomorphine
autoantibodies
autoimmune basal ganglia encephalitis
basal ganglia
basal ganglia, lesion of
basal ganglia, lesion, bilateral
CAT scan
CAT scan, emission
CAT scan, emission, abnormal
cerebral dominance
children
dopamine agonist
dopamine receptor
dopamine receptor, D2
dystonia
encephalitis
encephalitis, autoimmune
encephalopathy
encephalopathy, progressive
hepatolenticular degeneration(Wilson's disease)
immunotherapy
L-dopa
mental status, abnormal
MRI
MRI, abnormal
MRI, diffusion weighted
MRI, disappearing lesion on
multiple system atrophy
neuroprotective agents
neurotransmitter
Parkinson disease
Parkinson disease, on-off phenomena in
Parkinson disease, treatment of
penicillamine
pergolide
pleocytosis of cerebrospinal fluid
progressive supranuclear palsy
psychiatric problems in neurologic disorders
review article
schizophrenia
single photon emission computed tomography
striatal encephalitis
striatonigral degeneration
striatum, lesion of
striatum, lesion of, bilateral
treatment of neurologic disorder
Showing articles 0 to 50 of 925 Next >>

Treatable Bilateral Striatal Lesions Related to Anti-Dopamine 2 Receptor
Neurol 91:98-101, Marques-Matos, C.,et al, 2018

Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995

Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994

Schizophrenia as a Brain Disease, The Dopamine Receptor Story
Arch Neurol 50:1093-1095, 10971993., Seeman,P., 1993

Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993

Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993

Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992

123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992

Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992

Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989

Dopamine D2 Receptor Density Remains Constant in Treated Parkinson's Disease
Ann Neurol 19:487-492, Guttman,M.,et al, 1986

Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022

Glutamate Receptor D2 Serum Antibodies in Pediatric Opsoclonus Myoclonus Ataxia Syndrome
Neurol 91:e714-e723, Berridge, G.,et al, 2018

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017

Practice Guideline Summary: Treatment of Restless Leg Syndrome in Adults
Neurol 87:2585-2593, Winkelman, J.W.,et al, 2016

Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome
NEJM 370:621-631,667, Allen, R.P.,et al, 2014

Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014

Restless Genital Syndrome in Parkinson Disease
JAMA Neurol 71:1559-1561, Aquino, C.C.,et al, 2014

Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014

Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013

Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011

Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009

Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009

Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008

Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008

Headache and Pregnancy
The Neurologist 14:108-119, Menon,R. &Bushnell,C.D., 2008

Restless Arms
Lancet 371:530, Horvath,J.,et al, 2008

Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008

Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008

Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008

Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007

Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007

Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007

Pathologic Gambling in Patients with Restless Legs Syndrome Treated With Dopaminergic Agonists
Neurol 68:301-303, Tippmann-Peikert,M.,et al, 2007

Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007

Transdermal Rotigotine: Double-Blind, Placebo-Controlled Trial in Parkinson Disease
Arch Neurol 64:676-682, Jankovic,J.,et al, 2007

Advanced Parkinson Disease Treated with Rotigotine Transdermal System PREFER Study
Neurol 68:1262-1267, LeWitt,P.A.,et al, 2007

Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007

Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007

Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006

Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006

Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006

Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006

Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006



Showing articles 0 to 50 of 925 Next >>